Becton Dickinson (BDX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Matthew Taylor from Jefferies maintained a Buy rating on the stock and has a $255.00 price target.
Matthew Taylor’s rating is based on Becton Dickinson’s (BDX) ability to navigate a challenging operating environment while still delivering growth. Despite facing headwinds such as tariff uncertainties and a difficult second quarter, the company reported earnings per share (EPS) that exceeded consensus expectations. This performance was supported by strong growth in the Medical segment and improvements in gross and operating margins, which were driven by the BD Excellence operating system.
Furthermore, BDX’s strategic initiatives, including the planned separation of its Biosciences and Diagnostic Solutions business, are expected to unlock additional value. Although the company has lowered its forward guidance due to external pressures, Taylor believes that BDX’s underlying strengths and strategic moves position it well for future growth. As a result, he maintains a Buy rating, albeit with a revised price target reflecting the current market challenges.
In another report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $224.00 price target.
BDX’s price has also changed moderately for the past six months – from $235.240 to $169.540, which is a -27.93% drop .